Genetics of AD and PD 745
Miller DW, Ahmad R, Hague S, Baptista MJ, Canet-Aviles R, McLendon C, Carter DM, Zhu
PP, Stadler J, Chandran J, Klinefelter GR, Blackstone C, Cookson MR (2003) L166P mutant
DJ-1, causative for recessive Parkinson’s disease, is degraded through the ubiquitin-proteasome
system. J Biol Chem 278:36588–36595
Miller DW, Hague SM, Clarimon J, Baptista M, Gwinn-Hardy K, Cookson MR, Singleton AB
(2004) Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus
triplication. Neurology 62:1835–1838
Mineur YS, McLoughlin D, Crusio WE, Sluyter F, Huynh LX (2005) Genetic mouse models of
Alzheimer’s disease Social behavior deficits in the Fmr 1 mutant mouse Genetic dissection of
learning and memory in mice. Neural Plast 12:299–310
Mitsumoto A, Nakagawa Y (2001) DJ-1 is an indicator for endogenous reactive oxygen species
elicited by endotoxin. Free Radic Res 35:885–893
Mitsumoto A, Nakagawa Y, Takeuchi A, Okawa K, Iwamatsu A, Takanezawa Y (2001) Oxidized
forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal
levels of paraquat. Free Radic Res 35:301–310
Mizuno Y, Hattori N, Kubo S, Sato S, Nishioka K, Hatano T, Tomiyama H, Funayama M,
Machida Y, Mochizuki H (2008) Progress in the pathogenesis and genetics of Parkinson’s
disease. Philos Trans R Soc Lond B Biol Sci 363:2215–2227
Mizuta I, Satake W, Nakabayashi Y, Ito C, Suzuki S, Momose Y, Nagai Y, Oka A, Inoko H,
Fukae J, Saito Y, Sawabe M, Murayama S, Yamamoto M, Hattori N, Murata M, Toda T (2006)
Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic
Parkinson’s disease. Hum Mol Genet 15:1151–1158
Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, Capell A, Kaether C, Zheng H, Ghetti B,
Haass C, Steiner H (2002) Presenilin-1 mutations of leucine 166 equally affect the generation
of the Notch and APP intracellular domains independent of their effect on Abeta 42 production.
Proc Natl Acad Sci U S A 99:8025–8030
Moisoi N, Klupsch K, Fedele V, East P, Sharma S, Renton A, Plun-Favreau H, Edwards RE,
Teismann P, Esposti MD, Morrison AD, Wood NW, Downward J, Martins LM (2008)
Mitochondrial dysfunction triggered by loss of HtrA2 results in the activation of a brain-specific
transcriptional stress response. Cell Death Differ 16(3):449–464

Moore DJ, Zhang L, Dawson TM, Dawson VL (2003) A missense mutation (L166P) in DJ-1,
linked to familial Parkinson’s disease, confers reduced protein stability and impairs homo-
oligomerization. J Neurochem 87:1558–1567
Moore DJ, Zhang L, Troncoso J, Lee MK, Hattori N, Mizuno Y, Dawson TM, Dawson VL (2005)
Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress.
Hum Mol Genet 14:71–84
Mori H, Kondo T, Yokochi M, Matsumine H, Nakagawa-Hattori Y, Miyake T, Suda K, Mizuno Y
(1998) Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q.
Neurology 51:890–892
Mouatt-Prigent A, Muriel MP, Gu WJ, El Hachimi KH, Lucking CB, Brice A, Hirsch EC (2004)
Ultrastructural localization of parkin in the rat brainstem, thalamus and basal ganglia. J Neural
Transm 111:1209–1218
Mueller JC, Fuchs J, Hofer A, Zimprich A, Lichtner P, Illig T, Berg D, Wullner U, Meitinger T,
Gasser T (2005) Multiple regions of alpha-synuclein are associated with Parkinson’s disease.
Ann Neurol 57:535–541
Mullan M (1992) Familial Alzheimer’s disease: second gene locus located. BMJ 305:1108–1109
Munhoz RP, Sa DS, Rogaeva E, Salehi-Rad S, Sato C, Medeiros H, Farrer M, Lang AE (2004)
Clinical findings in a large family with a parkin ex3delta40 mutation. Arch Neurol 61:701–704
Munoz E, Tolosa E, Pastor P, Marti MJ, Valldeoriola F, Campdelacreu J, Oliva R (2002) Relative
high frequency of the c.255delA parkin gene mutation in Spanish patients with autosomal
recessive parkinsonism. J Neurol Neurosurg Psychiatry 73:582–584
Murrell J, Farlow M, Ghetti B, Benson MD (1991) A mutation in the amyloid precursor protein
associated with hereditary Alzheimer’s disease. Science 254:97–99
746 L.M. Bekris et al.
Myhre R, Steinkjer S, Stormyr A, Nilsen GL, Zayyad HA, Horany K, Nusier MK, Klungland H
(2008) Significance of the parkin and PINK1 gene in Jordanian families with incidences of
young-onset and juvenile parkinsonism. BMC Neurol 8:47
Nagakubo D, Taira T, Kitaura H, Ikeda M, Tamai K, Iguchi-Ariga SM, Ariga H (1997) DJ-1,
a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem
Biophys Res Commun 231:509–513

Nagy Z, Esiri MM, Jobst KA, Johnston C, Litchfield S, Sim E, Smith AD (1995) Influence of
the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in
Alzheimer’s disease. Neuroscience 69:757–761
Naito S, Mochizuki H, Yasuda T, Mizuno Y, Furusaka M, Ikeda S, Adachi T, Shimizu HM,
Suzuki J, Fujiwara S, Okada T, Nishikawa K, Aoki S, Wada K (2006) Characterization of
multimetric variants of ubiquitin carboxyl-terminal hydrolase L1 in water by small-angle
neutron scattering. Biochem Biophys Res Commun 339:717–725
Najim al-Din AS, Wriekat A, Mubaidin A, Dasouki M, Hiari M (1994) Pallido-pyramidal degener-
ation, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol Scand
89:347–352
Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, Aghai E, Reches A, Bembi B,
Zimran A (1996) Occurrence of Parkinson’s syndrome in type I Gaucher disease. QJM 89:
691–694
Neve RL, Finch EA, Dawes LR (1988) Expression of the Alzheimer amyloid precursor gene
transcripts in the human brain. Neuron 1:669–677
Nicholl DJ, Vaughan JR, Khan NL, Ho SL, Aldous DE, Lincoln S, Farrer M, Gayton JD, Davis
MB, Piccini P, Daniel SE, Lennox GG, Brooks DJ, Williams AC, Wood NW (2002) Two large
British kindreds with familial Parkinson’s disease: a clinico-pathological and genetic study.
Brain 125:44–57
Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, Rudolph A,
Wojcieszek J, Pfeiffer RF, Foroud T (2009) Mutations in GBA are associated with familial
Parkinson disease susceptibility and age at onset. Neurology 72:310–316
Nicoll JA, Roberts GW, Graham DI (1995) Apolipoprotein E epsilon 4 allele is asso-
ciated with deposition of amyloid beta-protein following head injury. Nat Med 1:
135–137
Nishikawa K, Li H, Kawamura R, Osaka H, Wang YL, Hara Y, Hirokawa T, Manago Y,
Amano T, Noda M, Aoki S, Wada K (2003) Alterations of structure and hydrolase activity of
parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem
Biophys Res Commun 304:176–183
Nishioka K, Hayashi S, Farrer MJ, Singleton AB, Yoshino H, Imai H, Kitami T, Sato K, Kuroda R,

Tomiyama H, Mizoguchi K, Murata M, Toda T, Imoto I, Inazawa J, Mizuno Y, Hattori N (2006)
Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson’s disease. Ann Neurol
59:298–309
Nukada H, Kowa H, Saitoh T, Tazaki Y, Miura S (1978) [A big family of paralysis agitans (author’s
transl)]. Rinsho Shinkeigaku 18:627–634
Nussbaum RL, Ellis CE (2003) Alzheimer’s disease and Parkinson’s disease. N Engl J Med
348:1356–1364
Oliveira SA, Scott WK, Martin ER, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern
MB, Hiner BC, Ondo WG, Allen FH Jr., Scott BL, Goetz CG, Small GW, Mastaglia F, Stajich
JM, Zhang F, Booze MW, Winn MP, Middleton LT, Haines JL, Pericak-Vance MA, Vance JM
(2003) Parkin mutations and susceptibility alleles in late-onset Parkinson’s disease. Ann Neurol
53:624–629
Oliveri RL, Zappia M, Annesi G, Annesi F, Spadafora P, Pasqua AA, Tomaino C, Nicoletti G,
Bosco D, Messina D, Logroscino G, Manobianca G, Epifanio A, Morgante L, Savettieri G,
Quattrone A (2001) The parkin gene is not a major susceptibility locus for typical late-onset
Parkinson’s disease. Neurol Sci 22:73–74
Genetics of AD and PD 747
Olzmann JA, Brown K, Wilkinson KD, Rees HD, Huai Q, Ke H, Levey AI, Li L, Chin LS
(2004) Familial Parkinson’s disease-associated L166P mutation disrupts DJ-1 protein folding
and function. J Biol Chem 279:8506–8515
Osaka H, Wang YL, Takada K, Takizawa S, Setsuie R, Li H, Sato Y, Nishikawa K, Sun YJ,
Sakurai M, Harada T, Hara Y, Kimura I, Chiba S, Namikawa K, Kiyama H, Noda M, Aoki S,
Wada K (2003) Ubiquitin carboxy-terminal hydrolase L 1 binds to and stabilizes monoubiquitin
in neuron. Hum Mol Genet 12:1945–1958
Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A,
Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS,
de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB (2004) Cloning
of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44:
595–600
Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, Shen J (2004)

Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem
279:18614–18622
Palmert MR, Golde TE, Cohen ML, Kovacs DM, Tanzi RE, Gusella JF, Usiak MF, Younkin LH,
Younkin SG (1988) Amyloid protein precursor messenger RNAs: differential expression in
Alzheimer’s disease. Science 241:1080–1084
Pals P, Lincoln S, Manning J, Heckman M, Skipper L, Hulihan M, Van den Broeck M, De Pooter T,
Cras P, Crook J, Van Broeckhoven C, Farrer MJ (2004) alpha-Synuclein promoter confers
susceptibility to Parkinson’s disease. Ann Neurol 56:591–595
Pandey N, Schmidt RE, Galvin JE (2006) The alpha-synuclein mutation E46K promotes aggrega-
tion in cultured cells. Exp Neurol 197:515–520
Periquet M, Latouche M, Lohmann E, Rawal N, De Michele G, Ricard S, Teive H, Fraix V,
Vidailhet M, Nicholl D, Barone P, Wood NW, Raskin S, Deleuze JF, Agid Y, Durr A, Brice A
(2003) Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain
126:1271–1278
Pesah Y, Pham T, Burgess H, Middlebrooks B, Verstreken P, Zhou Y, Harding M, Bellen H, Mardon
G (2004) Drosophila parkin mutants have decreased mass and cell size and increased sensitivity
to oxygen radical stress. Development 131:2183–2194
Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L,
Winblad B (2001) Current concepts in mild cognitive impairment. Arch Neurol 58:1985–1992
Petit A, Kawarai T, Paitel E, Sanjo N, Maj M, Scheid M, Chen F, Gu Y, Hasegawa H, Salehi-
Rad S, Wang L, Rogaeva E, Fraser P, Robinson B, St George-Hyslop P, Tandon A (2005)
Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated
by Parkinson disease-related mutations. J Biol Chem 280:34025–34032
Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW (1987) Astrocytes synthesize apolipoprotein E
and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 917:148–161
Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S (1993) Apolipoprotein E
polymorphism and Alzheimer’s disease. Lancet 342:697–699
Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, Sanges G, Stenroos
ES, Pho LT, Schaffer AA, Lazzarini AM, Nussbaum RL, Duvoisin RC (1996) Mapping of a
gene for Parkinson’s disease to chromosome 4q21-q23. Science 274:1197–1199

Ponte P, Gonzalez-DeWhitt P, Schilling J, Miller J, Hsu D, Greenberg B, Davis K, Wallace W,
Lieberburg I, Fuller F (1988) A new A4 amyloid mRNA contains a domain homologous to
serine proteinase inhibitors. Nature 331:525–527
Pramstaller PP, Schlossmacher MG, Jacques TS, Scaravilli F, Eskelson C, Pepivani I, Hedrich K,
Adel S, Gonzales-McNeal M, Hilker R, Kramer PL, Klein C (2005) Lewy body Parkinson’s
disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol 58:411–422
Prihar G, Fuldner RA, Perez-Tur J, Lincoln S, Duff K, Crook R, Hardy J, Philips CA, Venter
C, Talbot C, Clark RF, Goate A, Li J, Potter H, Karran E, Roberts GW, Hutton M, Adams
MD (1996) Structure and alternative splicing of the presenilin-2 gene. NeuroReport 7:
1680–1684
748 L.M. Bekris et al.
Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J (2006) Synapse formation
and function is modulated by the amyloid precursor protein. J Neurosci 26:7212–7221
Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, Horikoshi Y,
Kametani F, Maeda M, Saido TC, Wang R, Ihara Y (2005) Longer forms of amyloid beta
protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J
Neurosci 25:436–445
Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M (2008)
Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence
review for a clinical practice guideline. Ann Intern Med 148:379–397
Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF,
Wriekat AL, Roeper J, Al-Din A, Hillmer AM, Karsak M, Liss B, Woods CG, Behrens MI,
Kubisch C (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2,
encoding a lysosomal type 5 P-type ATPase. Nat Genet 38:1184–1191
Rapp A, Gmeiner B, Huttinger M (2006) Implication of apoE isoforms in cholesterol metabolism
by primary rat hippocampal neurons and astrocytes. Biochimie 88:473–483
Raschetti R, Albanese E, Vanacore N, Maggini M (2007) Cholinesterase inhibitors in mild
cognitive impairment: a systematic review of randomised trials. PLoS Med 4:e338
Raux G, Guyant-Marechal L, Martin C, Bou J, Penet C, Brice A, Hannequin D, Frebourg T,
Campion D (2005) Molecular diagnosis of autosomal dominant early onset Alzheimer’s

disease: an update. J Med Genet 42:793–795
Reiner O, Horowitz M (1988) Differential expression of the human glucocerebrosidase-coding
gene. Gene 73:469–478
Reiner O, Wigderson M, Horowitz M (1988) Structural analysis of the human glucocerebrosidase
genes. DNA 7:107–116
Reiner O, Wilder S, Givol D, Horowitz M (1987) Efficient in vitro and in vivo expression of human
glucocerebrosidase cDNA. DNA 6:101–108
Ren Y, Zhao J, Feng J (2003) Parkin binds to alpha/beta tubulin and increases their ubiquitination
and degradation. J Neurosci 23:3316–3324
Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E (2002)
Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from
the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68:568–578
Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K,
Tsuda T et al (1995) Familial Alzheimer’s disease in kindreds with missense mutations in a
gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature 376:775–778
Rogan S, Lippa CF (2002) Alzheimer’s disease and other dementias: a review. Am J Alzheimers
Dis Other Demen 17:11–17
Rohe CF, Montagna P, Breedveld G, Cortelli P, Oostra BA, Bonifati V (2004) Homozygous PINK1
C-terminus mutation causing early-onset parkinsonism. Ann Neurol 56:427–431
Roses AD (2006) On the discovery of the genetic association of Apolipoprotein E genotypes and
common late-onset Alzheimer disease. J Alzheimers Dis 9:361–366
Roses AD, Saunders AM, Alberts MA, Strittmatter WJ, Schmechel D, Gorder E, Pericak-Vance
MA (1995) Apolipoprotein E E4 allele and risk of dementia. J Am Med Assoc 273:374–375;
author reply 375–376
Rudzinski LA, Fletcher RM, Dickson DW, Crook R, Hutton ML, Adamson J, Graff-Radford NR
(2008) Early onset familial Alzheimer Disease with spastic paraparesis, dysarthria, and seizures
and N135S mutation in PSEN1. Alzheimer Dis Assoc Disord 22:299–307
Saigoh K, Wang YL, Suh JG, Yamanishi T, Sakai Y, Kiyosawa H, Harada T, Ichihara N, Wakana S,
Kikuchi T, Wada K (1999) Intragenic deletion in the gene encoding ubiquitin carboxy-terminal
hydrolase in gad mice. Nat Genet 23:47–51

Sandbrink R, Masters CL, Beyreuther K (1994) Similar alternative splicing of a non-homologous
domain in beta A4-amyloid protein precursor-like proteins. J Biol Chem 269:14227–14234
Sasaki H, Yukiue H, Moriyama S, Kobayashi Y, Nakashima Y, Kaji M, Fukai I, Kiriyama M,
Yamakawa Y, Fujii Y (2001) Expression of the protein gene product 9.5, PGP9.5, is correlated
with T-status in non-small cell lung cancer. Jpn J Clin Oncol 31:532–535
Genetics of AD and PD 749
Sastre M, Steiner H, Fuchs K, Capell A, Multhaup G, Condron MM, Teplow DB, Haass C (2001)
Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site
corresponding to the S3 cleavage of Notch. EMBO Rep 2:835–841
Sato N, Imaizumi K, Manabe T, Taniguchi M, Hitomi J, Katayama T, Yoneda T, Morihara T,
Yasuda Y, Takagi T, Kudo T, Tsuda T, Itoyama Y, Makifuchi T, Fraser PE, St George-Hyslop
P, Tohyama M (2001) Increased production of beta-amyloid and vulnerability to endoplasmic
reticulum stress by an aberrant spliced form of presenilin 2. J Biol Chem 276:2108–2114
Sato C, Morgan A, Lang AE, Salehi-Rad S, Kawarai T, Meng Y, Ray PN, Farrer LA, St George-
Hyslop P, Rogaeva E (2005) Analysis of the glucocerebrosidase gene in Parkinson’s disease.
Mov Disord 20:367–370
Schlehe JS, Lutz AK, Pilsl A, Lämmermann K, Grgur K, Henn IH, Tatzelt J, Winklhofer KF (2008)
Aberrant folding of pathogenic Parkin mutants: aggregation versus degradation. J Biol Chem
283:13771–13779
Schellenberg GD (1995) Genetic dissection of Alzheimer disease, a heterogeneous disorder. Proc
Natl Acad Sci U S A 92:8552–8559
Schellenberg GD, Bird TD, Wijsman EM, Orr HT, Anderson L, Nemens E, White JA, Bonnycastle
L, Weber JL, Alonso ME et al (1992) Genetic linkage evidence for a familial Alzheimer’s
disease locus on chromosome 14. Science 258:668–671
Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M,
Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi
R, Wasco W, Lannfelt L, Selkoe D, Younkin S (1996) Secreted amyloid beta-protein similar to
that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2
and APP mutations linked to familial Alzheimer’s disease. Nat Med 2:864–870
Schlossmacher MG, Frosch MP, Gai WP, Medina M, Sharma N, Forno L, Ochiishi T, Shimura H,

Sharon R, Hattori N, Langston JW, Mizuno Y, Hyman BT, Selkoe DJ, Kosik KS (2002) Parkin
localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol
160:1655–1667
Schroeter EH, Ilagan MX, Brunkan AL, Hecimovic S, Li YM, Xu M, Lewis HD, Saxena MT, De
Strooper B, Coonrod A, Tomita T, Iwatsubo T, Moore CL, Goate A, Wolfe MS, Shearman M,
Kopan R (2003) A presenilin dimer at the core of the gamma-secretase enzyme: insights from
parallel analysis of Notch 1 and APP proteolysis. Proc Natl Acad Sci U S A 100:13075–13080
Schupf N, Sergievsky GH (2002) Genetic and host factors for dementia in Down’s syndrome. Br J
Psychiatry 180:405–410
Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766
Serneels L, Dejaegere T, Craessaerts K, Horre K, Jorissen E, Tousseyn T, Hebert S, Coolen M,
Martens G, Zwijsen A, Annaert W, Hartmann D, De Strooper B (2005) Differential contribu-
tion of the three Aph1 genes to gamma-secretase activity i n vivo. Proc Natl Acad Sci U S A
102:1719–1724
Serretti A, Artioli P, Quartesan R, De Ronchi D (2005) Genes involved in Alzheimer’s disease, a
survey of possible candidates. J Alzheimers Dis 7:331–353
Setsuie R, Wada K (2007) The functions of UCH-L1 and its relation to neurodegenerative diseases.
Neurochem Int 51:105–111
Setsuie R, Wang YL, Mochizuki H, Osaka H, Hayakawa H, Ichihara N, Li H, Furuta A, Sano Y, Sun
YJ, Kwon J, Kabuta T, Yoshimi K, Aoki S, Mizuno Y, Noda M, Wada K (2007) Dopaminergic
neuronal loss in transgenic mice expressing the Parkinson’s disease-associated UCH-L1 I93M
mutant. Neurochem Int 50:119–129
Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M,
Whaley J, Swindlehurst C et al (1992) Isolation and quantification of soluble Alzheimer’s
beta-peptide from biological fluids. Nature 359:325–327
Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S (1997) Skeletal and CNS defects in
Presenilin-1-deficient mice. Cell 89:629–639
Sherrington R, Froelich S, Sorbi S, Campion D, Chi H, Rogaeva EA, Levesque G, Rogaev EI,
Lin C, Liang Y, Ikeda M, Mar L, Brice A, Agid Y, Percy ME, Clerget-Darpoux F, Piacentini
750 L.M. Bekris et al.

S, Marcon G, Nacmias B, Amaducci L, Frebourg T, Lannfelt L, Rommens JM, George-Hyslop
PH St (1996) Alzheimer’s disease associated with mutations in presenilin 2 is rare and variably
penetrant. Hum Mol Genet 5:985–988
Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G,
Holman K et al (1995) Cloning of a gene bearing missense mutations in early-onset familial
Alzheimer’s disease. Nature 375:754–760
Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, C hiba T,
Tanaka K, Suzuki T (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-
protein ligase. Nat Genet 25:302–305
Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y,
Kosik KS, Selkoe DJ (2001) Ubiquitination of a new form of alpha-synuclein by parkin from
human brain: implications for Parkinson’s disease. Science 293:263–269
Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai XD, McKay DM, Tintner R,
Frangione B et al (1992) Production of the Alzheimer amyloid beta protein by normal
proteolytic processing. Science 258:126–129
Silveira-Moriyama L, Guedes LC, Kingsbury A, Ayling H, Shaw K, Barbosa ER, Bonifati V, Quinn
NP, Abou-Sleiman P, Wood NW, Petrie A, Sampaio C, Ferreira JJ, Holton J, Revesz T, Lees
AJ (2008) Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data.
Neurology 71:1021–1026
Silvestri L, Caputo V, Bellacchio E, Atorino L, Dallapiccola B, Valente EM, Casari G (2005)
Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive
parkinsonism. Hum Mol Genet 14:3477–3492
Sing CF, Davignon J (1985) Role of the apolipoprotein E polymorphism in determining normal
plasma lipid and lipoprotein variation. Am J Hum Genet 37:268–285
Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T,
Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson
MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K (2003) alpha-
Synuclein locus triplication causes Parkinson’s disease. Science 302:841
Sisodia SS, Koo EH, Beyreuther K, Unterbeck A, Price DL (1990) Evidence that beta-
amyloid protein in Alzheimer’s disease is not derived by normal processing. Science 248:

492–495
Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM, Ross
CA (2005) Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2
induces neuronal degeneration. Proc Natl Acad Sci U S A 102:18676–18681
Specht CG, Schoepfer R (2001) Deletion of the alpha-synuclein locus in a subpopulation of
C57BL/6 J inbred mice. BMC Neurosci 2:11
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-
synuclein in Lewy bodies. Nature 388:839–840
Spitz M, Rozenberg R, Pereira Lda V, Reis Barbosa E (2008) Association between Parkinson’s
disease and glucocerebrosidase mutations in Brazil. Parkinsonism Relat Disord 14:58–62
Srinivasula SM, Gupta S, Datta P, Zhang Z, Hegde R, Cheong N, Fernandes-Alnemri T, Alnemri
ES (2003) Inhibitor of apoptosis proteins are substrates for the mitochondrial serine protease
Omi/HtrA2. J Biol Chem 278:31469–31472
Stratman NC, Castle CK, Taylor BM, Epps DE, Melchior GW, Carter DB (2005) Isoform-specific
interactions of human apolipoprotein E to an intermediate conformation of human Alzheimer
amyloid-beta peptide. Chem Phys Lipids 137:52–61
Strauss KM, Martins LM, Plun-Favreau H, Marx FP, Kautzmann S, Berg D, Gasser T, Wszolek Z,
Müller T, Bornemann A, Wolburg H, Downward J, Riess O, Schulz JB, Krüger R (2005) Loss
of function mutations in the gene encoding Omi/HtrA2 in Parkinson’s disease. Hum Mol Genet
14:2099–2111
Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr., Eckman C, Golde TE, Younkin SG (1994)
An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein
precursor (beta APP717) mutants. Science 264:1336–1340
Genetics of AD and PD 751
Suzuki Y, Imai Y, Nakayama H, Takahashi K, Takio K, Takahashi R (2001) A serine protease,
HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol
Cell 8:613–621
Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H (2004) DJ-1 has a role in
antioxidative stress to prevent cell death. EMBO Rep 5:213–218
Takahashi R, Deveraux Q, Tamm I, Welsh K, Assa-Munt N, Salvesen GS, Reed JC (1998) A single

BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem 273:7787–7790
Takahashi-Niki K, Niki T, Taira T, Iguchi-Ariga SM, Ariga H (2004) Reduced anti-oxidative
stress activities of DJ-1 mutants found in Parkinson’s disease patients. Biochem Biophys Res
Commun 320:389–397
Takahashi H, Ohama E, Suzuki S, Horikawa Y, Ishikawa A, Morita T, Tsuji S, Ikuta F (1994)
Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 44:
437–441
Takasugi N, Tomita T, Hayashi I, T suruoka M, Niimura M, Takahashi Y, Thinakaran G, Iwatsubo
T (2003) The role of presenilin cofactors in the gamma-secretase complex. Nature 422:
438–441
Tan EK, Chai A, Teo YY, Zhao Y, Tan C, Shen H, Chandran VR, Teoh ML, Yih Y, Pavanni R,
Wong MC, Puvan K, Lo YL, Yap E (2004a) Alpha-synuclein haplotypes implicated in risk of
Parkinson’s disease. Neurology 62:128–131
Tan EK, Puong KY, Chan DK, Yew K, Fook-Chong S, Shen H, Ng PW, Woo J, Yuen Y, Pavanni R,
Wong MC, Puvan K, Zhao Y (2005a) Impaired transcriptional upregulation of Parkin promoter
variant under oxidative stress and proteasomal inhibition: clinical association. Hum Genet
118:484–488
Tan E K, Puong KY, Fook-Chong S, Chua E, Shen H, Yuen Y, Pavanni R, Wong MC, Puvan K, Zhao
Y (2006a) C ase-control study of UCHL1 S18Y variant in Parkinson’s disease. Mov Disord
21:1765–1768
Tan EK, Shen H, Tan JM, Lim KL, Fook-Chong S, Hu WP, Paterson MC, Chandran VR, Yew K,
Tan C, Yuen Y, Pavanni R, Wong MC, Puvan K, Zhao Y (2005b) Differential expression of
splice variant and wild-type parkin in sporadic Parkinson’s disease. Neurogenetics 6:179–184
Tan EK, Skipper LM (2007) Pathogenic mutations in Parkinson disease. Hum Mutat 28:
641–653
Tan EK, Tan C, Zhao Y, Yew K, Shen H, Chandran VR, Teoh ML, Yih Y, Pavanni R, Wong MC
(2004b) Genetic analysis of DJ-1 in a cohort Parkinson’s disease patients of different ethnicity.
Neurosci Lett 367:109–112
Tan LC, Tanner CM, Chen R, Chan P, Farrer M, Hardy J, Langston JW (2003) Marked variation
in clinical presentation and age of onset in a family with a heterozygous parkin mutation. Mov

Disord 18:758–763
Tan EK, Tong J, Fook-Chong S, Yih Y, Wong MC, Pavanni R, Zhao Y (2007) Glucocerebrosidase
mutations and risk of Parkinson disease in Chinese patients. Arch Neurol 64:1056–1058
Tan EK, Yew K, Chua E, Puvan K, Shen H, Lee E, Puong KY, Zhao Y, Pavanni R, Wong MC,
Jamora D, de Silva D, Moe KT, Woon FP, Yuen Y, Tan L (2006b) PINK1 mutations in sporadic
early-onset Parkinson’s disease. Mov Disord 21:789–793
Tan EK, Yew K, Chua E, Shen H, Jamora RD, Lee E, Puong KY, Zhao Y, Pavanni R, Wong
MC, Puvan K, Yih Y, Tan LC (2005c) Analysis of PINK1 in Asian patients with familial
parkinsonism. Clin Genet 68:468–470
Tanaka S, Nakamura S, Ueda K, Kameyama M, Shiojiri S, Takahashi Y, Kitaguchi N, Ito H (1988)
Three types of amyloid protein precursor mRNA in human brain: their differential expression
in Alzheimer’s disease. Biochem Biophys Res Commun 157:472–479
Tandon A, Fraser P (2002) The presenilins. Genome Biol 3:s3014; review
Tang MX, Maestre G, Tsai WY, Liu XH, Feng L, Chung WY, Chun M, Schofield P, Stern Y, Tycko
B, Mayeux R (1996) Relative risk of Alzheimer disease and age-at-onset distributions, based on
APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York
City. Am J Hum Genet 58:574–584
752 L.M. Bekris et al.
Tanzi RE, McClatchey AI, Lamperti ED, Villa-Komaroff L, Gusella JF, Neve RL (1988) Protease
inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer’s
disease. Nature 331:528–530
Tassin J, Durr A, de Broucker T, Abbas N, Bonifati V, De Michele G, Bonnet AM, Broussolle E,
Pollak P, Vidailhet M, De Mari M, Marconi R, Medjbeur S, Filla A, Meco G, Agid Y, Brice
A (1998) Chromosome 6-linked autosomal recessive early-onset Parkinsonism: linkage in
European and Algerian families, extension of the clinical spectrum, and evidence of a small
homozygous deletion in one family. The French Parkinson’s Disease Genetics Study Group,
and the European Consortium on Genetic Susceptibility in Parkinson’s Disease. Am J Hum
Genet 63:88–94
Terry RD, Gonatas NK, Weiss M (1964) Ultrastructural Studies in Alzheimer’s Presenile
Dementia. Am J Pathol 44:269–297

Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H (2006) The development of amyloid beta
protein deposits in the aged brain. Sci Aging Knowledge Environ 2006(6) re1
Theuns J, Del-Favero J, Dermaut B, van Duijn CM, Backhovens H, Van den Broeck MV,
Serneels S, Corsmit E, Van Broeckhoven CV, Cruts M (2000) Genetic variability in the
regulatory region of presenilin 1 associated with risk for Alzheimer’s disease and variable
expression. Hum Mol Genet 9:325–331
Toft M, Pielsticker L, Ross OA, Aasly JO, Farrer MJ (2006) Glucocerebrosidase gene mutations
and Parkinson disease in the Norwegian population. Neurology 66:415–417
Tsai MS, Tangalos EG, Petersen RC, Smith GE, Schaid DJ, Kokmen E, Ivnik RJ, Thibodeau
SN (1994) Apolipoprotein E: risk factor for Alzheimer disease. Am J Hum Genet 54:
643–649
Turner PR, O’Connor K, Tate WP, Abraham WC (2003) Roles of amyloid precursor protein and
its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70:1–32
Uchihara T, Duyckaerts C, He Y, Kobayashi K, Seilhean D, Amouyel P, Hauw JJ (1995) ApoE
immunoreactivity and microglial cells in Alzheimer’s disease brain. Neurosci Lett 195:5–8
Uversky VN (2003) A protein-chameleon: conformational plasticity of alpha-synuclein, a disor-
dered protein involved in neurodegenerative disorders. J Biomol Struct Dyn 21:211–234
Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D,
Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi
S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW
(2004) Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science
304:1158–1160
Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, Ialongo T, Frontali M, Albanese A, Wood
NW (2001) Localization of a novel locus for autosomal recessive early-onset parkinsonism,
PARK6, on human chromosome 1p35-p36. Am J Hum Genet 68:895–900
Vande Walle L, Lamkanfi M, Vandenabeele P (2008) The mitochondrial serine protease
HtrA2/Omi: an overview. Cell Death Differ 15:453–460
Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S,
Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere
AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M (1999) Beta-

secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic
protease BACE. Science 286:735–741
Verhagen AM, Silke J, Ekert PG, Pakusch M, Kaufmann H, Connolly LM, Day CL, Tikoo A,
Burke R, Wrobel C, Moritz RL, Simpson RJ, Vaux DL (2002) HtrA2 promotes cell death
through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins.
J Biol Chem 277:445–454
von Coelln R, Dawson VL, Dawson TM (2004a) Parkin-associated Parkinson’s disease. Cell Tissue
Res 318:175–184
VonCoellnR,ThomasB,SavittJM,LimKL,SasakiM,HessEJ,DawsonVL,DawsonTM
(2004b) Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl
Acad Sci U S A 101:10744–10749
Genetics of AD and PD 753
Walker LC, Ibegbu CC, Todd CW, Robinson HL, Jucker M, LeVine H 3rd, Gandy S (2005)
Emerging prospects for the disease-modifying treatment of Alzheimer’s disease. Biochem
Pharmacol 69:1001–1008
Walter J, Kaether C, Steiner H, Haass C (2001) The cell biology of Alzheimer’s disease: uncovering
the secrets of secretases. Curr Opin Neurobiol 11:585–590
Wang C, Tan J M, Ho MW, Zaiden N, Wong SH, Chew CL, Eng PW, Lim TM, Dawson TM,
Lim KL (2005) Alterations in the solubility and intracellular localization of parkin by several
familial Parkinson’s disease-linked point mutations. J Neurochem 93:422–431
Waragai M, Wei J, Fujita M, Nakai M, Ho GJ, Masliah E, Akatsu H, Yamada T, Hashimoto M
(2006) Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson’s disease.
Biochem Biophys Res Commun 345:967–972
Weidemann A, Eggert S, Reinhard FB, Vogel M, Paliga K, Baier G, Masters CL, Beyreuther K,
Evin G (2002) A novel epsilon-cleavage within the transmembrane domain of the Alzheimer
amyloid precursor protein demonstrates homology with Notch processing. Biochemistry
41:2825–2835
Weidemann A, Konig G, Bunke D, Fischer P, Salbaum JM, Masters CL, Beyreuther K (1989)
Identification, biogenesis, and localization of precursors of Alzheimer’s disease A4 amyloid
protein. Cell 57:115–126

West AB, Maraganore D, Crook J, Lesnick T, Lockhart PJ, Wilkes KM, Kapatos G, Hardy
JA, Farrer MJ (2002) Functional association of the parkin gene promoter with idiopathic
Parkinson’s disease. Hum Mol Genet 11:2787–2792
West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM
(2005) Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase
activity. Proc Natl Acad Sci U S A 102:16842–16847
Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH,
Carlson GA, Younkin SG, Ashe KH (2002) The relationship between Abeta and memory in the
Tg2576 mouse model of Alzheimer’s disease. J Neurosci 22:1858–1867
Wigderson M, Firon N, Horowitz Z, Wilder S, Frishberg Y, Reiner O, Horowitz M (1989)
Characterization of mutations in Gaucher patients by cDNA cloning. Am J Hum Genet
44:365–377
Wilkinson KD, Lee KM, Deshpande S, Duerksen-Hughes P, Boss JM, Pohl J (1989) The neuron-
specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 246:670–673
Williams DR, Hadeed A, al-Din AS, Wreikat AL, Lees AJ (2005) Kufor Rakeb disease: autosomal
recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze
palsy, and dementia. Mov Disord 20:1264–1271
Wing SS (2003) Deubiquitinating e nzymes – the importance of driving in reverse along the
ubiquitin-proteasome pathway. Int J Biochem Cell Biol 35:590–605
Wintermeyer P, Kruger R, Kuhn W, Muller T, Woitalla D, Berg D, Becker G, Leroy E,
Polymeropoulos M, Berger K, Przuntek H, Schols L, Epplen JT, Riess O (2000) Mutation
analysis and association studies of the UCHL1 gene in German Parkinson’s disease patients.
NeuroReport 11:2079–2082
Wolfe MS (2007) When loss is gain: reduced presenilin proteolytic function leads to increased
Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease.
EMBO Rep 8:136–140
Wolfe MS, De Los Angeles J, Miller DD, Xia W, Selkoe DJ (1999a) Are presenilins
intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer’s
disease. Biochemistry 38:11223–11230
Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ (1999b) Two transmem-

brane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase
activity. Nature 398:513–517
Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, Morrison A, Lwin A,
Colegial C, Allman JM, Schiffmann R (2004) Neuropathology provides clues to the patho-
physiology of Gaucher disease. Mol Genet Metab 82:192–207
754 L.M. Bekris et al.
Wood JG, Mirra SS, Pollock NJ, Binder LI (1986) Neurofibrillary tangles of Alzheimer disease
share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc
Natl Acad Sci U S A 83:4040–4043
Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ, Strongosky AJ,
Zimprich A, Muller-Myhsok B, Farrer MJ, Gasser T, Calne DB, Dickson DW (2004)
Autosomal dominant parkinsonism associated with variable synuclein and t au pathology.
Neurology 62:1619–1622
Wu YR, Chen CM, Chao CY, Ro LS, Lyu RK, Chang KH, Lee-Chen GJ (2007) Glucocerebrosidase
gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J Neurol
Neurosurg Psychiatry 78:977–979
Xu PT, Gilbert JR, Qiu HL, Ervin J, Rothrock-Christian TR, Hulette C, Schmechel DE (1999)
Specific regional transcription of apolipoprotein E in human brain neurons. Am J Pathol
154:601–611
Xu YH, Wenstrup R, Grabowski GA (1995) Effect of cellular type on expression of acid beta-
glucosidase: implications for gene therapy in Gaucher disease. Gene Ther 2:647–654
Xu J, Zhong N, Wang H, Elias JE, Kim CY, Woldman I, Pifl C, Gygi SP, Geula C, Yankner BA
(2005) The Parkinson’s disease-associated DJ-1 protein is a transcriptional co-activator that
protects against neuronal apoptosis. Hum Mol Genet 14:1231–1241
Yamamura Y, Sobue I, Ando K, Iida M, Yanagi T (1973) Paralysis agitans of early onset with
marked diurnal fluctuation of symptoms. Neurology 23:239–244
Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Kasai Y, Ito K, Akiyama S, Nagasaka T,
Nakao A (2002) PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res 8:192–195
Yang QH, Church-Hajduk R, Ren J, Newton ML, Du C (2003) Omi/HtrA2 catalytic cleavage
of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in

apoptosis. Genes Dev 17:1487–1496
Yang F, Jiang Q, Zhao J, Ren Y, Sutton MD, Feng J (2005) Parkin stabilizes microtubules through
strong binding mediated by three independent domains. J Biol Chem 280:17154–17162
Yokota T, Sugawara K, Ito K, Takahashi R, Ariga H, Mizusawa H (2003) Down regulation of DJ-1
enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem Biophys
Res Commun 312:1342–1348
Yoshikai S, Sasaki H, Doh-ura K, Furuya H, Sakaki Y (1990) Genomic organization of the human
amyloid beta-protein precursor gene. Gene 87:257–263
Yu H, Saura CA, Choi SY, Sun LD, Yang X, Handler M, Kawarabayashi T, Younkin L, Fedeles B,
Wilson MA, Younkin S, Kandel ER, Kirkwood A, Shen J (2001) APP processing and synaptic
plasticity in presenilin-1 conditional knockout mice. Neuron 31:713–726
Zabetian CP, Hutter CM, Yearout D, Lopez AN, Factor SA, Griffith A, Leis BC, Bird TD, Nutt JG,
Higgins DS, Roberts JW, Kay DM, Edwards KL, Samii A, Payami H (2006) LRRK2 G2019S
in families with Parkinson disease who originated from Europe and the Middle East: evidence
of two distinct founding events beginning two millennia ago. Am J Hum Genet 79:752–758
Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J,
Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes
JG (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body
dementia. Ann Neurol 55:164–173
Zhang ZJ, Burgunder JM, An XK, Wu Y, Chen WJ, Zhang JH, Wang YC, Xu YM, Gou
YR, Yuan GG, Mao XY, Peng R (2008) Lack of evidence for association of a UCH-L1
S18Y polymorphism with Parkinson’s disease in a Han-Chinese population. Neurosci Lett
442:200–202
Zhang L, Shimoji M, Thomas B, Moore DJ, Yu SW, Marupudi NI, Torp R, Torgner IA, Ottersen
OP, Dawson TM, Dawson VL (2005) Mitochondrial localization of the Parkinson’s disease
related protein DJ-1: implications for pathogenesis. Hum Mol Genet 14:2063–2073
Zhao G, Mao G, Tan J, Dong Y, Cui MZ, Kim SH, Xu X (2004) Identification of a new presenilin-
dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein. J
Biol Chem 279:50647–50650